Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 7/20 | 0.85 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.85 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.85 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.85 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.85 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.85 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL30301300 | 0.94 | OPRD1 (0.85) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8374708 | 0.93 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL149700 | 0.93 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL15055206 | 0.93 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2443249 | 0.93 | OPRD1 (0.89) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL21359130 | 0.92 | OPRD1 (0.92) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL27547724 | 0.92 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL24599520 | 0.92 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL12125412 | 0.92 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL6393384 | 0.92 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440489-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-10-14 | — | — | US | claimed |
| CN-118105390-A | Method for treating addiction | 细胞内治疗公司 | 2024-05-31 | — | — | CN | claimed |
| US-20240165111-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-05-23 | — | — | US | claimed |
| US-11844757-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-12-19 | — | — | US | claimed |
| US-11794009-B2 | Devices, systems and methods for treating urological and gastrointestinal disorders by electrical stimulation of the foot | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-10-24 | — | — | US | claimed |
| US-20230181576-A9 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-06-15 | — | — | US | claimed |
| US-20220296591-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2022-09-22 | — | — | US | claimed |
| US-11376249-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-07-05 | — | — | US | claimed |
| US-20220088014-A1 | METHODS OF TREATING ADDICTION | INTRA-CELLULAR THERAPIES, INC. | 2022-03-24 | — | — | US | claimed |
| US-20210370059-A1 | Devices, Systems and Methods for Treating Urological and Gastrointestinal Disorders by Electrical Stimulation of the Foot | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-12-02 | — | — | US | claimed |
| WO-2020154519-A2 | METHODS OF TREATING ADDICTION | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-07-30 | — | — | WO | claimed |
| EP-3169318-B1 | ABUSE DETERRENT OPIOD/OPIOD-ANTAGONIST TRANSDERMAL PATCH | BUZZZ PHARMACEUTICALS LTD (IE) | 2020-04-01 | — | — | EP | claimed |
| US-10238648-B2 | Abuse deterrent opioid/opioid-antagonist transdermal patch | BUZZZ PHARMACEUTICALS LTD. (IE) | 2019-03-26 | — | — | US | claimed |
| US-20170361091-A1 | Devices, Systems and Methods for Treating Urological and Gastrointestinal Disorders by Electrical Stimulation of the Foot | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-12-21 | — | — | US | claimed |
| EP-3237057-A1 | DEVICES, SYSTEMS AND METHODS FOR TREATING UROLOGICAL AND GASTROINTESTINAL DISORDERS BY ELECTRICAL STIMULATION OF THE FOOT | University of Pittsburgh - Of the Commonwealth System of Higher Education (US) | 2017-11-01 | — | — | EP | claimed |
| US-20170209429-A1 | ABUSE DETERRENT OPIOD/OPIOD-ANTAGONIST TRANSDERMAL PATCH | BUZZZ PHARMACEUTICALS LIMITED (IE) | 2017-07-27 | — | — | US | claimed |
| EP-3169318-A1 | ABUSE DETERRENT OPIOD/OPIOD-ANTAGONIST TRANSDERMAL PATCH | Buzzz Pharmaceuticals Limited (IE) | 2017-05-24 | — | — | EP | claimed |
| WO-2017046581-A1 | COMPOSITION COMPRISING CAV2.2 CALCIUM CHANNEL BLOCKER AND OPIOID | CALCHAN LIMITED (GB) | 2017-03-23 | — | — | WO | claimed |
| WO-2016106182-A1 | DEVICES, SYSTEMS AND METHODS FOR TREATING UROLOGICAL AND GASTROINTESTINAL DISORDERS BY ELECTRICAL STIMULATION OF THE FOOT | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-06-30 | — | — | WO | claimed |
| WO-2016009064-A1 | ABUSE DETERRENT OPIOD/OPIOD-ANTAGONIST TRANSDERMAL PATCH | BUZZZ PHARMACEUTICALS LIMITED (IE) | 2016-01-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376249-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRD1 1/4885OPRK1 2/4885 |
| US-20240165111-A1 | ORGANIC COMPOUNDS | HTR2C, HTR2A, HTR3A | OPRM1 21/4885OPRD1 17/4885OPRK1 14/4885 |
| US-20230181576-A9 | ORGANIC COMPOUNDS | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRD1 1/4885OPRK1 2/4885 |
| US-20220088014-A1 | METHODS OF TREATING ADDICTION | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
| US-20220296591-A1 | ORGANIC COMPOUNDS | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRD1 1/4885OPRK1 2/4885 |
| US-11844757-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRD1 1/4885OPRK1 2/4885 |
| US-12440489-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRD1 1/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.